The World Health Organization (WHO) adopted the eleventh revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-11) at its World Health Assembly meeting in May 2019. It addition to other major changes, ICD-11 includes a new classification for chronic pain as well as new groups of codes for chronic pain conditions. After a decade of preparation, ICD-11 will become effective in January 2022. The advance release allows countries to plan how to use the new version and train health professionals.
Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions.